Myocardial indium-111-antimyosin uptake in essential hypertension.
OBJECTIVE
Evaluation of myocardial uptake of (111)In-anti-myosin antibodies in patients with essential hypertension for the verification of our hypothesis that it may increase in stage 1 in the left ventricle as a result of myocardial damage.


METHODS
Twelve men (mean age: 59+/-2.4 years) suffering from angina like symptoms and essential hypertension in clinical stage 1 according to the JNC-VI criteria were included into the study. These patients showed normal perfusion as revealed by thallium-201 myocardial study and coronary angiography. Left ventricular mass index was determined in echocardiography. Planar antimyosin images were obtained 48 h after the intravenous injection of the tracer. Heart to lung ratios were calculated as a parameter of myocardial tracer uptake using appropriate region of interests; values>1.52 were considered as abnormal.


RESULTS
We observed increased anti-myosin uptake (mean: 1.71+/-0.12) consistent with myocardial damage in 11 of 12 patients. Nine of 12 patients had a left ventricular hypertrophy with left ventricular mass index values (mean: 131 g/m(2)+/-9.48) above 115 g/m(2). Heart to lung ratio was correlated significantly to left ventricular mass index (r = 0.902, p<0.001) and duration of hypertension (r = 0.948, p<0.001).


CONCLUSIONS
Our results suggest that (111)In-antimyosin imaging may indicate myocyte damage in early phases of hypertensive heart disease.
Unlü
M
M
Department of Nuclear Medicine, Gazi University School of Medicine, Ankara, Turkey. mustafaunlutr@yahoo.com
Temiz
N H
NH
Cengel
A
A
D000368:Aged; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure; D006801:Humans; D006973:Hypertension / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D007190:Indapamide / Q000627:therapeutic use; D007205:Indium Radioisotopes / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D009218:Myosins / Q000493:pharmacokinetics; D009942:Organometallic Compounds / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging
D000911:Antibodies, Monoclonal; D000959:Antihypertensive Agents; D007205:Indium Radioisotopes; D009942:Organometallic Compounds; C058899:imciromab pentetate; D009218:Myosins; D007190:Indapamide